French University Hospital starts trial of Omalizumab in chronic urticaria
The clinical trial of drug survival of Omalizumab in chronic urticarial (Retrospective Multicentric Study) has commenced.
University Hospital is recruiting patients in the following locations Uh Montpellier (34295, Montpellier, France).
Chronic urticaria affects up to 1% of the population. Chronic urticaria refractory to updosing antihistamines can benefit from Omalizumab. Efficacy and good tolerance have already been demonstrated in real-life large cohorts of patients. A 6 months treatment duration is proposed before evaluating the efficacy and discontinuating the treatment in the absence of adequate response. Mean duration of chronic urticaria is 3 to 5 years with high standard deviations. Therefore, optimal duration of treatment with Omalizumab is unknown and discontinuation modalities differ between physicians.
The aim of this study is to evaluate the mean duration between initiation and first discontinuation of Omalizumab in patients treated for chronic urticaria and explore the different factors influencing this duration and its outcome.
To accomplish this, the investigators will conduct a restrospective analyse of all patients treated with Omalizumab for chronic urticaria from 2010 to 2020 in the major French hospital reference centers for chronic urticaria management : Paris, Lyon, Grenoble, Lille, Bordeaux, Nantes, Rouen, Saint-Etienne, Montpellier.
On 1 July, first participant was enrolled in a clinical study.
French referal hospital centers of chronic urticaria management are involved in the process.
The link to the study details.
